PCSK9 inhibitors

Jul 21, 2026

Novartis Wins FDA Traditional Approval for Fabhalta to Treat Primary IgAN Novartis announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for slowing the progression of kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) wh...

Sep 08, 2025

The Unmet Need in Cholesterol Management Cardiovascular Diseases (CVDs) continue to be one of the leading causes of morbidity and mortality worldwide, primarily driven by underlying lipid disorders, including Hypercholesterolemia (familial and non-familial hypercholesterolemia), Dyslipidemia, Atherosclerotic Car...

Sep 05, 2025

The cardiovascular space has witnessed a surge in strategic collaborations and licensing deals as companies race to address the rising global burden of heart disease with next-generation therapies. Recent transactions reflect a sharpened focus on precision cardiology, novel protein targets, and RNA-based approaches...

Jun 10, 2025

Amylyx Pharmaceuticals Receives FDA Fast Track Designation for AMX0114 in ALS Amylyx Pharmaceuticals announced that the FDA has granted Fast Track designation to its investigational antisense oligonucleotide (ASO), AMX0114, for the treatment of amyotrophic lateral sclerosis (ALS). The candidate targets calpain-2...

Jan 29, 2024

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, encompassing conditions such as coronary artery disease and stroke. The growing occurrence of ASCVD, fueled by elevated risk factors, cardiovascular disease, and diabetes, is contributing to an expanding market f...

Oct 10, 2022

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...